|
TCFL5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.78239994880403E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.85850018602696E-10 |
| Normal-vs-Stage2 |
8.144000E-01 |
| Normal-vs-Stage3 |
1.59376999999683E-05 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
5.761700E-02 |
| Stage1-vs-Stage3 |
9.134400E-01 |
| Stage1-vs-Stage4 |
3.982600E-04 |
| Stage2-vs-Stage3 |
6.573800E-02 |
| Stage2-vs-Stage4 |
5.540600E-03 |
| Stage3-vs-Stage4 |
5.484300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93180027530104E-10 |
| Normal-vs-AfricanAmerican |
1.72869496495309E-11 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
9.104300E-02 |
| Caucasian-vs-Asian |
1.395930E-03 |
| AfricanAmerican-vs-Asian |
4.122000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.04769999995391E-06 |
| Normal-vs-Female |
1.42199996222558E-09 |
| Male-vs-Female |
9.781600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
2.24979999999819E-05 |
| Normal-vs-Age(61-80Yrs) |
1.436050E-03 |
| Normal-vs-Age(81-100Yrs) |
9.435800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.856100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.426500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.556200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.518400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.994000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.422600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.45269999999964E-05 |
| Classical-VS-Follicular |
1.550090E-04 |
| Classical-VS-Other |
5.305000E-01 |
| Classical-VS-Normal |
2.40918396343659E-14 |
| Tall-VS-Follicular |
1.1678000000348E-06 |
| Tall-VS-Other |
4.677800E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.403170E-04 |
| Follicular-VS-Normal |
6.515200E-01 |
| Other-VS-Normal |
5.00399999991963E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.3076999999927E-05 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
5.63269999531713E-08 |
|
|
